← Leaderboards
L T Spencer
University Of Florida
$1,014,888
Attributed
$1,014,888
Total exposure
18
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $174K · FY2005–08$200K$150K$100K$50K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$1,014,888 · 18
By mechanism
K23$640,975 · 1
M01$373,913 · 17
Top collaborators
No co-investigators on record.
Most similar at University Of Florida
Same institution · by research overlap
- Terence R. Flotte$26,412,339
- Mark Louis Brantly$2,016,455
- Stephanie A S Staras$9,004,981
- Sihong Song$1,714,919
- Christopher E Forsmark$2,643,269
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisClinical ResearchHuman SubjectNeutrophilDefensinsHuman Therapy EvaluationBronchoscopyAlpha 1 AntitrypsinInflammationRespiratory Disorder ChemotherapyResearch PersonnelComputer Retrieval Of Information On Scientific Projects DatabaseResourcesRespiratory InfectionsUnited States National Institutes Of HealthInstitutionDrug Screening /EvaluationYoung Adult Human (21-34)GrantAdolescence (12-20)FundingSourceDouble-Blind MethodCystic Fibrosis Patients
Grant awards (25)
CLINICAL TRIAL: A MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED S$541
M01 · FY2008 · RR · contact PI
AIR-CF2 TRIAL WITH AZTREONAM LYSINATE FOR INHALATION IN CF PAT WITH P ARUGINOSA$19,832
M01 · FY2007 · RR · contact PI
AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS WITH PULMONARY P1$2,143
M01 · FY2007 · RR · contact PI
A MULTI-CENTER, PLACEBO-CONTROLLED, DOUBLE-BLINDED, RANDOMIZED STUDY OF DIABETE$2,143
M01 · FY2007 · RR · contact PI
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EURAND PANCREATIC ENM$535
M01 · FY2007 · RR · contact PI
STUDY OF ORAL THERACLEC-TOTAL IN CF SUBJECTS WITH EXOCRINE PANCREATIC INSUFF$100,348
M01 · FY2006 · RR · contact PI
AIR-CF2 TRIAL WITH AZTREONAM LYSINATE FOR INHALATION IN CF PAT WITH P ARUGINOSA$13,204
M01 · FY2006 · RR · contact PI
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY OF AEROSOLIZED$4,621
M01 · FY2006 · RR · contact PI
AZTREONAM LYSINATE FOR INHALATION IN CYSTIC FIBROSIS PATIENTS WITH PULMONARY P1$4,621
M01 · FY2006 · RR · contact PI
EVAL OF ANTI-INFLAMMATORY EFFECTS OF AZITHROMYCIN IN PTS W/CF$1,321
M01 · FY2006 · RR · contact PI
STUDY OF ORAL THERACLEC-TOTAL IN CF SUBJECTS WITH EXOCRINE PANCREATIC INSUFF$81,501
M01 · FY2005 · RR
A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY OF AEROSOLIZED$45,886
M01 · FY2005 · RR
EVAL OF ANTI-INFLAMMATORY EFFECTS OF AZITHROMYCIN IN PTS W/CF$21,917
M01 · FY2005 · RR
A BLINDED, MULTICTR, RAND, PLACEBO-CNTRLD TRIAL W/ AZTREONAM INHALATION IN CF PT$15,753
M01 · FY2005 · RR
THE ROLE OF ALPHA-DEFENSINS IN CYSTIC FIBROSIS LUNG DISEASE$8,903
M01 · FY2005 · RR
THE ROLE OF ALPHA-DEFENSINS IN CYSTIC FIBROSIS LUNG DISE$128,195
K23 · FY2004 · HL
The role of alpha-defensins in cystic fibrosis lung disease$32,960
M01 · FY2004 · RR
A Multicenter, Double-Blind, Placebo-Controlled, Phase II Study of Aerosolized$9,646
M01 · FY2004 · RR
Eval of Anti-Inflammatory Effects of Azithromycin in Pts w/CF$8,038
M01 · FY2004 · RR
THE ROLE OF ALPHA-DEFENSINS IN CYSTIC FIBROSIS LUNG DISE$128,195
K23 · FY2003 · HL
THE ROLE OF ALPHA-DEFENSINS IN CYSTIC FIBROSIS LUNG DISE$128,195
K23 · FY2002 · HL
THE ROLE OF ALPHA-DEFENSINS IN CYSTIC FIBROSIS LUNG DISE$128,195
K23 · FY2001 · HL
THE ROLE OF ALPHA-DEFENSINS IN CYSTIC FIBROSIS LUNG DISE$128,195
K23 · FY2000 · HL
A DEFENSINS IN CYSTIC FIBROSIS LUNG DISEASE$0
M01 · FY2000 · RR
A DEFENSINS IN CYSTIC FIBROSIS LUNG DISEASE$0
M01 · FY2000 · RR